Phase 1b evaluation of safety and activity of JK07 in heart failure with reduced ejection fraction

20 May 2023 (16:10 - 16:20)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Wai Hong Wilson Tang

Cleveland Clinic, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail

Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients with Chronic Heart Failure (MONITOR-HF): A randomized controlled clinical trial

Professor J. Brugts (Rotterdam, NL)

Presentation thumbnail

TRACER-HF: Trientine-HCL for treatment of heart failure and reduced ejection fraction

Professor J. Januzzi (Boston, US)

Presentation thumbnail

REDWOOD-HCM-Cohort 4: Aficamten in non-obstructive HCM

Doctor A. Masri (Portland, US)

Presentation thumbnail

Primary results of the Phase Ib proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR-cardiomyopathy

Doctor P. Garcia-Pavia (Majadahonda, ES)

Presentation thumbnail

Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study

Professor M. Fontana (London, GB)

Access the full session

Session thumbnail

Late breaking clinical trials: chronic HF and cardiomyopathies

The Event

Event poster

Heart Failure 2023

20 May 2023 16:10 CET

You may be interested in

Congress Presentation

TRACER-HF: Trientine-HCL for treatment of heart failure and reduced ejection fraction

Congress Presentation

Primary results of the Phase Ib proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR-cardiomyopathy

Congress Presentation

Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients with Chronic Heart Failure (MONITOR-HF): A randomized controlled clinical trial

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources